APP and Alzheimer disease: We first investigated, in a transgenic mouse model of AD-like pathology, whether DNA hypomethylation at the bace-1 gene is a downstream effect of the APP mutation and if so, whether the administration of SAM could reduce this hypomethylation, dampen the amyloid pathology, and offset associated cognitive deficits.